“Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s74. doi:10.25251/skin.6.supp.74.